Novel biomarker panel for colon cancer unveiled by proteomics

Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi® ) in the treatment of von Willebrand disease: a retrospective clinical study

Summary. The goal of therapy in patients with von Willebrand disease (vWD) is to correct the dual defect of primary haemostasis and intrinsic coagulation reflected by low levels of von Willebrand factor (vWF) and factor VIII coagulant activity (FVIII:C). Factor VIII/von Willebrand factor (FVIII/vWF) concentrates are currently the treatment of choice in vWD patients unresponsive to desmopressin (DDAVP). However, only few studies on their clinical use are available so far. The main objective of this study was to retrospectively evaluate the clinical efficacy of a highly purified, doubly virus-inactivated FVIII/vWF concentrate with a high content of FVIII/vWF (Fanhdi®). Twenty-two patients wit…

DIFFERENTIAL INFLUENCE OF HYPOXIA ON GENE EXPRESSION OF TUMORAL AND NON TUMORAL MAMMARY CELLS

Cancer metastasis is the result of a series of deregulated biological phenomena, including alterations of cell-cell and cell-matrix interactions and of other microenvironmental conditions such as the oxygen tissue supply. Hypoxia is a well-known driver of aggressive cancer phenotypes, indeed tumors with poor prognosis have higher proportions of anoxic and hypoxic areas1. The consequences of tumour hypoxia can be local or even systemic towards distant organs, and it can evoke diversified responses: whereas low oxygen concentration in tissue environments. (pO2 <7 mmHg) exerts anti-proliferative effects and promotes differentiation, apoptosis and/or necrosis on normal cells, the tumoral cells …

Proteomic profiling of Trastuzumab (Herceptin(R))-sensitive and -resistant SKBR-3 breast cancer cells.

BACKGROUND: The Human Epidermal Growth Factor Receptor 2 (HER-2), overexpressed in 25-30% of breast carcinomas (BC), is the therapeutic target for trastuzumab, a recombinant humanized monoclonal antibody. The initial response to trastuzumab is often followed by drug-insensitivity within one year. Several hypotheses have been raised to explain this event, but the mechanisms behind the responses to trastuzumab are still unclear. Aim: To study the effects of short and prolonged trastuzumab treatment on the proteomic profiles of HER-2-overexpressing SKBR-3 BC cells. MATERIALS AND METHODS: Cells were treated with trastuzumab to obtain sensitive and resistant clones. The drug effects were evaluat…

COMPARATIVE PROTEOMIC PROFILING OF NORMAL AND BREAST CANCER CELLS UNDER HYPOXIC CONDITIONS

influences emanating from the tissue microenvironment, such as cell-cell and cell-matrix interactions and other local pathophysiologic conditions as hypoxia. However the hypoxic effect may be different according to the cell conditions. For example, the low concentration of tissue oxygen (pO2 <7 mmHg) may exert anti-proliferative effects on normal cells and may induce differentiation or apoptosis and necrosis. On the other contrary, tumour cells likely react to hypoxic stress with an adaptive process through modification of gene expression that may confer an aggressive phenotype to cells, promoting their local and distant spread [1]. In general it is believed that hypoxic microenvironments i…